Hoyer Group Merges Petrolog and Gaslog into Contract Division
7. January 2021DSLV Answers Questions About the Brexit Trade Agreement
8. January 2021The Swiss logistics provider Kühne + Nagel has concluded an agreement with the US biotechnology company Moderna for the global distribution of the Corona vaccine. The contract includes storage and delivery in compliance with safety and temperature regulations.
(Cambridge, Mass. USA/Schindellegi/Switzerland) Moderna Inc., a biotechnology company developing RNA therapeutics and vaccines, and Kühne+Nagel, a leading global logistics company, announced today that they have entered into an international supply agreement for the distribution and storage of Moderna’s Covid-19 vaccines. This announcement follows the granting of conditional approval by the European Medicines Agency (EMA) for Moderna’s Covid-19 vaccine.
Kühne+Nagel will support the global distribution of vaccine doses from Moderna’s international supply chain based in Europe. This includes distribution to markets in Europe, Asia, the Middle East, and Africa, as well as parts of North and South America.
After Approval, Logistics is the Next Step
“We are proud to work with Kühne+Nagel from Europe to support the distribution of vaccines to global citizens. Following the recent approvals, this is another step closer to solving the pandemic and an exciting time for our companies and all stakeholders,” says Dan Staner, Vice President Head of EMEA Region, Moderna Inc.
The agreement includes the distribution and storage of the vaccine from Kühne+Nagel’s pharmaceutical hub in Europe. Kühne+Nagel will utilize its global network of over 230 branches to distribute the vaccine by road and air. In Europe alone, the company operates its own fleet of over 200 specialized pharmaceutical transport vehicles. Throughout all phases of transport and storage, product integrity will be maintained at the required temperature of -20°C.
Years of Expansion Pay Off
Robert Coyle, Senior Vice President, Pharma & Healthcare, Kühne + Nagel International AG, comments: “With today’s announcement, we take on the responsibility of distributing Moderna’s Covid-19 vaccine worldwide. We have been investing in our pharma and healthcare network and our global expert team for decades – we are now ready when it matters most.”
Kühne+Nagel’s logistics subsidiary QuickSTAT is also an integral part of Moderna’s vaccine supply chain, as it has supported the supply logistics for Phase II and Phase III clinical trials in the USA.
Kühne+Nagel has also signed partnerships with authorities in several countries for local storage and last-mile distribution, such as in the most populous federal state of Germany, North Rhine-Westphalia.
Photo: © Moderna
